Zachariae H, Thestrup-Pedersen K
Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark.
J Invest Dermatol. 1990 Dec;95(6 Suppl):206S-208S. doi: 10.1111/1523-1747.ep12875616.
Eleven patients suffering from cutaneous T-cell lymphoma (mycosis fungoides) were treated with recombinant interferon alpha-2A in combination (seven patients) or alone. Two patients, one in combined treatment, went into clinical complete remission, and five experienced partial remission. Two patients progressed during therapy, and two were nonevaluable because they stopped treatment early due to side effects. Dosages of interferon were from 3 to 36 million units daily for 3 months, and thereafter 3 times weekly. Etretinate (0.7 mg/kg) was given orally. The study showed that recombinant interferon alpha-2A in combination with etretinate or alone can induce remission of cutaneous T-cell lymphoma.
11例皮肤T细胞淋巴瘤（蕈样肉芽肿）患者接受了重组干扰素α-2A联合治疗（7例）或单独治疗。2例患者（1例联合治疗）实现了临床完全缓解，5例部分缓解。2例患者在治疗期间病情进展，2例因副作用提前停药而无法评估。干扰素剂量为每日300万至3600万单位，持续3个月，此后每周3次。口服依曲替酯（0.7mg/kg）。该研究表明，重组干扰素α-2A联合依曲替酯或单独使用均可诱导皮肤T细胞淋巴瘤缓解。
